# US 2026/0266800 A1 · Bodily fluid management system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0266800 A1
- Document ID: US20260266800A1
- Status: Published application
- Kind: A1
- Application number: 19/658,091
- Filed: 2026-04-24
- Published: 2026-09-10
- Earliest claimed: 2023-10-25
- Applicants: Starling Medical, Inc.
- Inventors: Hannah MCKENNEY; William Andrew HENDRICKS
- Web page: https://patentgrep.com/patent/US20260266800A1

## CPC

- G01N 33/493: urine
- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/14539: {for measuring pH}
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61B 5/207: {Sensing devices adapted to collect urine}
- A61B 5/7282: {Event detection, e.g. detecting unique waveforms indicative of a medical condition (cough events A61B5/0823; seizures A61B5/4094; sleep apnoea A61B5/4818)}
- A61B 10/007: {for taking urine samples (measuring urological functions A61B5/20; genital receptacles A61F5/451; urinals for bed-ridden persons A61G9/006)}
- G01N 15/075: by optical means
- G01N 21/31: Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry {(G01N21/72 takes precedence)}
- A61B 5/14535: {for measuring haematocrit}
- A61B 2560/0214: of power generation or supply
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Systems, devices, and methods herein may include a system for monitoring bodily fluid from a patient. In some embodiments, the system may be configured to collect bodily fluid samples from a patient periodically over time to determine a baseline bodily fluid composition. In some embodiments, the system may use spectrophotometry to determine the baseline bodily fluid composition for the patient. The system may be configured to compare a bodily fluid sample to the baseline bodily fluid composition to detect detecting changes in one or more characteristics of the bodily fluid sample (e.g., composition, absorption spectrum, etc.) from the baseline. Changes in the bodily fluid sample characteristics may be used to predict and/or detect abnormalities or infection for individualized diagnosis.

## Claims

### Claim 1

A method, comprising:
collecting, using a urine collection device configured to be disposed in a toilet, urine of a patient at a first time point or a first set of time points;
measuring one or more characteristics of the urine to determine baseline characteristics of the urine of the patient;
collecting, using the urine collection device, a test urine sample from the patient at a second time point;
measuring one or more characteristics of the test urine sample from the patient;
comparing the one or more characteristics of the test urine sample to the baseline characteristics of the urine of the patient; and
detecting or predicting a presence or absence of a pathological condition based on the comparison of the one or more characteristics of the test urine sample to the baseline characteristics of the urine.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
determining a baseline composition of the urine based on the baseline characteristics of the urine;
determining a composition of the test urine sample based on the one or more characteristics of the test urine sample;
comparing the composition of the test urine sample to the baseline composition of the urine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the urine collection device includes a lumen configured to receive the urine, the urine collection device further including one or more optical emitters and one or more optical sensors opposite the one or more optical emitters, the one or more optical sensors configured to measure light transmitted through the urine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the measuring one or more characteristics of the urine to determine the baseline characteristics of the urine includes:
performing spectrophotometry on the urine to determine a baseline spectral signature corresponding to the patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein the measuring the one or more characteristics of the test urine sample includes performing spectrophotometry on the test urine sample to determine a spectral signature of the test urine sample, the method further comprising:
comparing the spectral signature of the test urine sample to the baseline spectral signature of the patient.

### Claim 6 (depends on 4)

The method of claim 4, wherein the performing spectrophotometry on the urine includes measuring at least one of ultraviolet light, visible light, or infrared light transmitted through the urine.

### Claim 7 (depends on 5)

The method of claim 5, further comprising:
detecting a presence or absence of at least one of leukocytes or nitrites in the test urine sample based on the peaks of the spectral signature of the test urine sample; and
determining the patient has an infection based on the presence of at least one of the leukocytes or nitrites in the test urine sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the baseline characteristics are determined based on urine collected when the patient is not experiencing urinary symptoms.

### Claim 9 (depends on 5)

The method of claim 5, further comprising:
detecting a presence or absence of at least one of tumor markers, hematuria, or DNA/RNA fragments based on the spectral signature of the test urine sample; and
detecting or predicting a presence or absence of at least one of bladder, prostate, or renal cancer based on the presence or absence of at least one of the tumor markers, hematuria, or DNA/RNA fragments.

### Claim 10 (depends on 1)

The method of claim 1, wherein the one or more characteristics of the urine includes at least one of a presence of bacteria, a presence of white blood cells, a presence of nitrites, a presence of protein, a presence of red blood cells, a pH level, a glucose level, and/or a presence of casts.

### Claim 11 (depends on 1)

The method of claim 1, further comprising:
displaying to a user, via an external device operatively coupled to the urine collection device, at least one of the one or more characteristics of the test urine sample or a detected change in the one or more characteristics of the test urine sample from the baseline characteristics of the urine.

### Claim 12

A method, comprising:
collecting a bodily fluid sample from a patient through a lumen of a bodily fluid device such that the bodily fluid sample flows past one or more optical sensors of the bodily fluid device;
measuring, as the bodily fluid flows past the one or more optical sensors, a spectral signature of the bodily fluid sample;
detecting a concentration of one or more biomarkers in the bodily fluid sample based on a global peak pattern of the spectral signature of the bodily fluid sample, the global peak pattern including peaks from a plurality of compounds in the bodily fluid sample;
comparing the concentration of one or more biomarkers in the bodily fluid sample to a baseline composition of the bodily fluid of the patient; and
detecting or predicting a presence or absence of a pathological condition based on the comparing the concentration of the one or more biomarkers in the bodily fluid sample to the baseline composition of the bodily fluid of the patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more optical sensors are configured to measure at least one of ultraviolet light, visible light, or infrared light transmitted through the urine.

### Claim 14 (depends on 12)

The method of claim 12, wherein the detecting the concentration of the one or more biomarkers in the bodily fluid sample includes:
detecting the concentration of leukocytes or nitrites in the test urine sample based on the global peak pattern of the spectral signature of the bodily fluid sample; and
determining the patient has an infection based on the concentration of at least one of the leukocytes or nitrites in the bodily fluid sample.

### Claim 15 (depends on 12)

The method of claim 12, wherein the baseline characteristics are determined based on bodily fluid collected when the patient is not experiencing symptoms of infection or illness.

### Claim 16 (depends on 12)

The method of claim 12, wherein the one or more biomarkers includes at least one of a presence of bacteria, a presence of white blood cells, a presence of nitrites, a presence of protein, a presence of red blood cells, a pH level, a glucose level, a color, a clarity, and/or a presence of casts.

### Claim 17 (depends on 12)

The method of claim 12, wherein the detecting the concentration of the one or more biomarkers in the bodily fluid sample includes detecting a presence or absence of at least one of tumor markers, hematuria, or DNA/RNA fragments based on the global peak pattern of the spectral signature of the bodily fluid sample, and
the detecting or predicting the presence or absence of the pathological condition includes detecting or predicting a presence or absence of at least one of bladder, prostate, or renal cancer based on the presence or absence of at least one of the tumor markers, hematuria, or DNA/RNA fragments.

### Claim 18 (depends on 12)

The method of claim 12, further comprising:
displaying to a user, via an external device operatively coupled to the bodily fluid collection device, a composition of the bodily fluid sample based on the spectral signature of the bodily fluid sample or a detected change in the composition of the bodily fluid sample.

### Claim 19

A system, comprising:
a fluid collection device including lumen configured to receive bodily fluid from a patient, the fluid collection device including one or more sensors disposed near the lumen and configured to measure one or more signals corresponding to the bodily fluid from the patient; and
a remote device configured to receive the one or more signals corresponding to the bodily fluid from the patient, the remote device including:
a memory configured to store information relating to the signals of the bodily fluid from the patient; and
a processor operatively coupled to the fluid collection device and the remote device, the processor configured to:
measure one or more characteristics of the bodily fluid of the patient collected at a first time point or a first set of time points to determine baseline characteristics of the bodily fluid of the patient;
measure one or more characteristics of a test bodily fluid sample of the patient collected at a second time point;
compare the one or more characteristics of the test bodily fluid sample to the one or more baseline characteristics of the bodily fluid of the patient; and
detect or predict a presence or absence of a pathological condition based on the comparison of the one or more characteristics of the test bodily fluid sample to the one or more baseline characteristics of the bodily fluid.

### Claim 20 (depends on 19)

The system of claim 19, wherein the one or more sensors include one or more optical emitters and one or more optical sensors opposite the one or more optical emitters, the one or more optical sensors configured to measure light transmitted through the bodily fluid.

### Claim 21 (depends on 20)

The system of claim 20, wherein the one or more optical sensors are configured to measure one or more ranges of wavelengths of light, each range of wavelengths of light corresponding to a target biomarker.

### Claim 22 (depends on 20)

The system of claim 20, wherein the one or more optical sensors are configured to measure at least one of ultraviolet light, visible light, or infrared light.

### Claim 23 (depends on 19)

The system of claim 19, wherein the one or more sensors are configured to measure microwave radiation transmitted through the test bodily fluid sample, and the processor further configured to:
determine a hydration of the user based on the microwave radiation transmitted through the test bodily fluid sample.

### Claim 24 (depends on 19)

The system of claim 19, wherein the one or more sensors are configured to measure radiowaves transmitted through the bodily fluid, the processor further configured to:
determine a baseline concentration of at least one of metabolites or proteins in the bodily fluid of the patient; and
determine a baseline concentration of at least one of metabolites or proteins in the test bodily fluid sample.

### Claim 25 (depends on 19)

The system of claim 19, wherein the one or more baseline characteristic of the bodily fluid includes a baseline spectral signature of the bodily fluid, and the one or more characteristics of the test bodily fluid sample includes a spectral signature of the test bodily fluid sample.

### Claim 26 (depends on 25)

The system of claim 25, wherein the processor is configured to determine at least one of a presence or a concentration of a target biomarker by analyzing a global peak pattern of the spectral signature of the test bodily fluid sample, the global peak pattern corresponding to a composite of peaks caused by the target biomarker and biomarkers associated with the target biomarker.

### Claim 27 (depends on 19)

The system of claim 19, wherein the bodily fluid of the patient is urine, and the fluid collection device is configured to be disposed on an inner surface of a toilet to collect the urine or configured to be coupled to a urinary catheter to collect the urine.

### Claim 28 (depends on 19)

The system of claim 19, wherein the fluid collection device further includes:
at least one of a humidity sensor or an absolute water vapor sensor configured to measure a humidity inside the fluid collection device and a humidity external to the fluid collection device.

### Claim 29 (depends on 19)

The system of claim 19, wherein the fluid collection device is powered using at least one of ambient light, heat from the bodily fluid sample, transducing a kinetic energy from the flow of the bodily fluid, or harvesting radiofrequency energy.

### Claim 30 (depends on 19)

The system of claim 19, wherein the fluid collection device further includes:
a cleaning reservoir configured to contain cleaning solution, the fluid collection device configured to expel cleaning solution to sterilize or provide scent to an environment surrounding the fluid collection device.

### Claim 31 (depends on 19)

The system of claim 19, wherein the remote device is a user device, the processor of the remote device further configured to:
display to a user at least one of:
(i) the one or more baseline characteristics of the bodily fluid of the patient,
(ii) the one or more characteristics of the test bodily fluid sample,
(iii) changes between the one or more baseline characteristics of the bodily fluid of the patient and the one or more characteristics of the test bodily fluid sample, or
(iv) the presence or absence of the pathological condition.

### Claim 32 (depends on 19)

The system of claim 19, wherein the fluid collection device includes a portable probe defining the lumen at an end thereof, the probe configured to be disposed into a reservoir of bodily fluid such that the bodily fluid fills the lumen to be analyzed by the fluid collection device.
